ReviewCurrent cardiology reports2019
Pluripotent Stem Cell-Derived Cardiomyocyte Transplantation for Heart Disease Treatment.
Review in Current cardiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Application of autologous stem cells in the treatment of ischaemic cardiomyopathy with heart failure after myocardial infarction.Journal of stem cells & regenerative medicine · 2025Article
- Injectable biodegradable microcarriers for iPSC expansion and cardiomyocyte differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- CT-Visible Microspheres Enable Whole-Body In Vivo Tracking of Injectable Tissue Engineering Scaffolds.Advanced healthcare materials · 2024Article
- Advancing Cardiomyocyte Maturation: Current Strategies and Promising Conductive Polymer-Based Approaches.Advanced healthcare materials · 2024Review
- Non-human primate studies for cardiomyocyte transplantation-ready for translation?Frontiers in pharmacology · 2024Review
- Novel Molecular Vehicle-Based Approach for Cardiac Cell Transplantation Leads to Rapid Electromechanical Graft-Host Coupling.International journal of molecular sciences · 2023Article
- Trajectory reconstruction identifies dysregulation of perinatal maturation programs in pluripotent stem cell-derived cardiomyocytes.Cell reports · 2023Article
- Genome Editing and Cardiac Regeneration.Advances in experimental medicine and biology · 2023Article
- Polymer Kernels as Compact Carriers for Suspended Cardiomyocytes.Micromachines · 2022Article
- Tissue Engineering Techniques for Induced Pluripotent Stem Cell Derived Three-Dimensional Cardiac Constructs.Tissue engineering. Part B, Reviews · 2022Review
- Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.Pharmaceutics · 2022Review
- A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine.Stem cell reviews and reports · 2021Review
- Transplantation of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Cardiac Regenerative Therapy.Frontiers in cardiovascular medicine · 2021Review
- Neuronal differentiation strategies: insights from single-cell sequencing and machine learning.Development (Cambridge, England) · 2020Review
- Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy.International journal of molecular sciences · 2020Review
- Tanshinone IIA promotes cardiac differentiation and improves cell motility by modulating the Wnt/β‑catenin signaling pathway.Molecular medicine reports · 2020Article
- Quantitative Evaluation of the Sarcomere Network of Human hiPSC-Derived Cardiomyocytes Using Single-Molecule Localization Microscopy.International journal of molecular sciences · 2020Article
- Stem cells: a new way of therapy for cardiovascular disorders.Stem cell investigation · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiovascular disease is the leading cause of mortality worldwide. Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) have great potential to treat heart disease, owing to their capacity of engraftment and remuscularization in the host heart after transplantation. In the current review, we provide an overview of PSC-CMs for clinical transplantation. RECENT
findingsStudies have shown that PSC-CMs can survive, engraft, and form gap junctions after transplantation, with functional benefit. Engrafted PSC-CMs matured gradually in host hearts. Only in a large animal model, transient ventricular arrhythmias were detected, mainly because of the ectopic pacing from the grafted PSC-CMs. Although intense immunosuppression is unavoidable in xenotransplantation, immunosuppression remains necessary for MHC-matched allogenic non-human primate PSC-CMs transplantation. This review offers insights on how PSC-CMs contribute to functional benefit after transplantation to injured non-human primate hearts. We believe that PSC-CM transplantation represents a potentially novel treatment for ischemic heart diseases, provided that several technological and biological limitations can be overcome.
Indexed as
Identifiers
31228011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.